Higuchi Osamu
National Hospital Organization Nagasaki Kawatana Medical Center.
Brain Nerve. 2018 Apr;70(4):419-426. doi: 10.11477/mf.1416201014.
Myasthenia gravis (MG) is one of the autoantibody-mediated neuroimmunological diseases. Autoantibodies to the muscle-type nicotinic acetylcholine receptor (AChR) were detected in more than 80% of MG patients. The gene structure and pathogenicity of some AChR antibodies produced in MG have already been identified and elucidated, respectively. Therefore, the AChR antibody is similar in nature to innovative drug development targets with respect to MG treatment. Here, we discuss the development of molecular target drugs for AChR antibody-positive MG.
重症肌无力（MG）是自身抗体介导的神经免疫性疾病之一。超过80%的MG患者可检测到针对肌肉型烟碱型乙酰胆碱受体（AChR）的自身抗体。MG中产生的一些AChR抗体的基因结构和致病性已分别得到鉴定和阐明。因此，就MG治疗而言，AChR抗体在本质上与创新药物开发靶点相似。在此，我们讨论针对AChR抗体阳性MG的分子靶向药物的开发。
